Danielle Brill
Stock Analyst at Truist Securities
(3.87)
# 718
Out of 5,149 analysts
100
Total ratings
45.56%
Success rate
12.37%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRON Disc Medicine | Maintains: Buy | $114 → $83 | $64.36 | +28.96% | 8 | Feb 27, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $86 → $95 | $64.53 | +47.22% | 4 | Feb 25, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $169 → $140 | $131.14 | +6.76% | 9 | Feb 17, 2026 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $33 → $38 | $26.20 | +45.04% | 3 | Jan 29, 2026 | |
| TECX Tectonic Therapeutic | Maintains: Buy | $64 → $60 | $24.40 | +145.95% | 3 | Jan 8, 2026 | |
| IMVT Immunovant | Maintains: Hold | $16 → $22 | $26.71 | -17.63% | 6 | Jan 8, 2026 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $48 → $45 | $28.27 | +59.18% | 9 | Jan 8, 2026 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $56 → $63 | $55.45 | +13.62% | 2 | Jan 8, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $535 → $530 | $318.65 | +66.33% | 3 | Jan 8, 2026 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $105 → $190 | $131.51 | +44.48% | 4 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $7.36 | +538.59% | 1 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $474.27 | - | 3 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $20.34 | +17.99% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $20 → $52 | $9.03 | +475.86% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $20.02 | - | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $79 | $58.53 | +34.97% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $18 | $8.69 | +107.13% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $150 | $15.87 | +845.18% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $184.02 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $748.72 | -19.20% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $22.50 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $43.79 | +14.18% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $28.48 | +79.07% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $180 → $100 | $8.00 | +1,150.00% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $64.39 | - | 9 | Sep 18, 2023 |
Disc Medicine
Feb 27, 2026
Maintains: Buy
Price Target: $114 → $83
Current: $64.36
Upside: +28.96%
BridgeBio Pharma
Feb 25, 2026
Maintains: Buy
Price Target: $86 → $95
Current: $64.53
Upside: +47.22%
Neurocrine Biosciences
Feb 17, 2026
Maintains: Buy
Price Target: $169 → $140
Current: $131.14
Upside: +6.76%
Centessa Pharmaceuticals
Jan 29, 2026
Maintains: Buy
Price Target: $33 → $38
Current: $26.20
Upside: +45.04%
Tectonic Therapeutic
Jan 8, 2026
Maintains: Buy
Price Target: $64 → $60
Current: $24.40
Upside: +145.95%
Immunovant
Jan 8, 2026
Maintains: Hold
Price Target: $16 → $22
Current: $26.71
Upside: -17.63%
Harmony Biosciences Holdings
Jan 8, 2026
Maintains: Buy
Price Target: $48 → $45
Current: $28.27
Upside: +59.18%
Dianthus Therapeutics
Jan 8, 2026
Maintains: Buy
Price Target: $56 → $63
Current: $55.45
Upside: +13.62%
Alnylam Pharmaceuticals
Jan 8, 2026
Maintains: Buy
Price Target: $535 → $530
Current: $318.65
Upside: +66.33%
Palvella Therapeutics
Dec 16, 2025
Maintains: Buy
Price Target: $105 → $190
Current: $131.51
Upside: +44.48%
Oct 14, 2025
Initiates: Buy
Price Target: $47
Current: $7.36
Upside: +538.59%
Sep 3, 2025
Initiates: Market Perform
Price Target: n/a
Current: $474.27
Upside: -
Jul 21, 2025
Initiates: Buy
Price Target: $24
Current: $20.34
Upside: +17.99%
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $9.03
Upside: +475.86%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $20.02
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $58.53
Upside: +34.97%
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $8.69
Upside: +107.13%
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $15.87
Upside: +845.18%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $184.02
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $748.72
Upside: -19.20%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $22.50
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $43.79
Upside: +14.18%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $28.48
Upside: +79.07%
Nov 14, 2023
Maintains: Outperform
Price Target: $180 → $100
Current: $8.00
Upside: +1,150.00%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $64.39
Upside: -